PharmAust Ltd – Human Cancer Trial Advancing to Second Patient

ASX Release – Tuesday 21 October 2014 

PharmAust Limited (ASX; PAA & PAAO) is pleased to report that it is now advancing to the treatment of the second patient in its “First in Man” trial with PPL-1. Following the approval of the study by the Royal Adelaide Hospital research Ethics Committee in April 2014, the Company commenced recruitment and treatment of the first patient with its anti-cancer drug PPL-1. Unfortunately, the first patient passed away due to reasons unrelated to the study drug and this has understandably resulted in a standard process of investigations resulting in delays in the treatment of the second patient.

CMAX with the assistance and guidance of the Principal Investigator, Professor Michael Brown, will resubmit the ethics application to the Royal Adelaide Hospital Ethic Committee to seek approval for advancing the clinical trial.

To view the full ASX Release please, click here.